These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
23. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. Sellers J; Darby RR; Farooque A; Claassen DO Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099 [TBL] [Abstract][Full Text] [Related]
24. Can pimavanserin help patients with Parkinson disease psychosis? de la Cruz J; Canal C JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736 [TBL] [Abstract][Full Text] [Related]
25. Pimavanserin: First Global Approval. Markham A Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680 [TBL] [Abstract][Full Text] [Related]
26. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
27. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132 [TBL] [Abstract][Full Text] [Related]
28. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related]
29. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; Ketter TA; Cucchiaro J; Loebel A J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116 [TBL] [Abstract][Full Text] [Related]
30. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis. Wilby KJ; Johnson EG; Johnson HE; Ensom MHH Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039 [TBL] [Abstract][Full Text] [Related]
31. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700 [TBL] [Abstract][Full Text] [Related]
32. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904 [TBL] [Abstract][Full Text] [Related]
33. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
34. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland RH J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248 [TBL] [Abstract][Full Text] [Related]
35. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
36. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Citrome L Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634 [TBL] [Abstract][Full Text] [Related]
37. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654 [TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. Stahl SM CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570 [TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis. Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395 [No Abstract] [Full Text] [Related]
40. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]